196 results on '"Bonavita, Simona"'
Search Results
2. Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched study
3. Flexibility of brain dynamics is increased and predicts clinical impairment in relapsing-remitting but not in secondary progressive multiple sclerosis
4. Vitamin D Supplementation: Effect on Cytokine Profile in Multiple Sclerosis
5. Apparently isolated CNS involvement in Erdheim-Chester disease: Case report
6. Exploring Circulating Long Non-Coding RNAs in Mild Cognitive Impairment Patients’ Blood
7. Editorial: Bridging the gap between basic neurosciences and clinical neuroimmunology
8. Exploring Circulating Long Non-Coding RNAs in Mild Cognitive Impairment Patients’ Blood
9. Ocrelizumab Extended Interval Dosing in Primary Progressive Multiple Sclerosis: An Italian Experience
10. Assisted Reproductive Technology and Disease Management in Infertile Women with Multiple Sclerosis
11. Cost-Analysis of Telemedicine Interventions Compared with Traditional Care in the Management of Chronic Neurological Diseases: A Systematic Review
12. Exercise and Parkinson’s Disease
13. Previous disease-modifying treatments influence T lymphocyte kinetics in people with multiple sclerosis switching to ocrelizumab
14. Validation of an iPad version of the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) (P3-3.010)
15. Effects of ocrelizumab on NK cell activation in Relapsing Multiple Sclerosis (P2-3.004)
16. Viral pericarditis following ocrelizumab in a multiple sclerosis patient
17. Health related quality of life in the domain of physical activity predicts confirmed disability progression in people with relapsing remitting multiple sclerosis
18. Validation of an iPad version of the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)
19. Sexual Dysfunction in People with Multiple Sclerosis: The Role of Disease Severity, Illness Perception, and Depression
20. Circulating long noncodingRNAs in Mild Cognitive Impairment patients’ blood
21. Epidemiological and Immune Profile Analysis of Italian Subjects with Endometriosis and Multiple Sclerosis
22. Alemtuzumab-Related Lymphocyte Subset Dynamics and Disease Activity or Autoimmune Adverse Events: Real-World Evidence
23. MRI and steroid-responsive encephalopathy associated with autoimmune thyroiditis: first report of conus medullaris involvement and literature review of the known neuroimaging profiles
24. Long-Term Neuromodulatory Effects of Repetitive Transcranial Magnetic Stimulation (rTMS) on Plasmatic Matrix Metalloproteinases (MMPs) Levels and Visuospatial Abilities in Mild Cognitive Impairment (MCI)
25. Clinically Manifest Infections Do Not Increase the Relapse Risk in People with Multiple Sclerosis Treated with Disease-Modifying Therapies: A Prospective Study
26. Immunomodulatory effects of ocrelizumab and candidate biomarkers for monitoring treatment response in multiple sclerosis
27. Reduced Clinical Connectome Fingerprinting in Multiple Sclerosis Predicts Fatigue Severity
28. Reduced clinical connectome fingerprinting in multiple sclerosis predicts fatigue severity
29. Association of vitamin D serum levels and vitamin D supplementation with B cell kinetics and disease activity in Multiple Sclerosis patients treated with ocrelizumab: an Italian multi-center study
30. Artificial intelligence will change MS care within the next 10 years: Commentary
31. Disease Reactivation in Secondary Progressive Multiple Sclerosis Patients Switching from Fingolimod to Siponimod: A Case Series
32. Machine learning techniques for prediction of multiple sclerosis progression
33. Unmet needs and gaps in the identification of secondary progression in multiple sclerosis: a Southern Italy healthcare professionals’ perspective
34. Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic
35. Editorial: Disease modifying therapies in multiple sclerosis
36. Validation of an iPad version of the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)
37. The impact of COVID-19 on people with multiple sclerosis: A comparison of Italian and United States cohorts
38. Optimal retreatment schedule of rituximab for neuromyelitis optica spectrum disorder: A systematic review
39. Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies
40. Integrated Cognitive Rehabilitation Home-Based Protocol to Improve Cognitive Functions in Multiple Sclerosis Patients: A Randomized Controlled Study
41. Is the pathology of posterior cortical atrophy clinically predictable?
42. Predictors of Cladribine Effectiveness and Safety in Multiple Sclerosis: A Real-World, Multicenter, 2-Year Follow-Up Study
43. Repetitive Transcranial Magnetic Stimulation (rTMS) of Dorsolateral Prefrontal Cortex May Influence Semantic Fluency and Functional Connectivity in Fronto-Parietal Network in Mild Cognitive Impairment (MCI)
44. Prognostic Markers of Ocrelizumab Effectiveness in Multiple Sclerosis: A Real World Observational Multicenter Study
45. Systematic Review on the Role of Lobar Cerebral Microbleeds in Cognition
46. Lymphopenia in Multiple Sclerosis patients treated with Ocrelizumab is associated with an effect on CD8 T cells
47. Pelvic Floor Dysfunctions and Their Rehabilitation in Multiple Sclerosis
48. Hemostasis Components as Therapeutic Targets in Autoimmune Demyelination
49. Family Planning in People With Multiple Sclerosis: A Plain Language Summary
50. The progressive loss of brain network fingerprints in Amyotrophic Lateral Sclerosis predicts clinical impairment
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.